The best oncology drugs in the world are most effective when we link them to the right patients. Diagnostics help us make that connection and strengthen personalized healthcare.
One in three female cancers is diagnosed as breast cancer. Contrary to popular belief, breast cancer isn't just one disease and it impacts men as well. Breast cancer is characterized by the expression, or lack of expression, of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). Targeted therapies exist to determine the most appropriate approach based on a patient's expression of these receptors.
We know having access to the most comprehensive diagnostic assays is essential to providing personalized cancer care.
Cervical cancer affects around 14,000 people with a cervix in the United States each year. The link between cervical cancer and human papillomavirus (HPV) is clear. Persistent HPV infections with high-risk genotypes account for almost all cervical cancer diagnoses.
Access to screenings and vaccinations can help prevent the development of cervical cancer. Treatment is more successful when persistent HPV infection is detected early and before it evolves into cancer.
Lung cancer is the second most common cancer for both men and women. There are many different types of lung cancer, and the two main subtypes are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Lung cancer diagnosis and treatment is complex, and we're committed to developing comprehensive diagnostic tools to improve a patient's healthcare journey.
A companion diagnostic (CDx) in oncology is a test that provides information about a patient’s tumor and informs whether an available drug therapy can be used that’s safe and effective for that individual patient. CDx are an important part of personalized medicine or patient-specific treatment.
The first CDx test approved by the FDA, in 1998, assessed cells that over-produce the HER2 protein for breast cancer patients.
Today, the list of companion diagnostics used to help treat tumors and cancers of the blood is expansive and growing.
Progress in cancer treatment has been made through molecular analysis and biomarker discovery. We can now leverage diagnostics insights to make informed timely, confident and personal treatment options. With over 50 years in oncology, we continue to develop innovative diagnostic solutions to transform cancer care.
